• ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    2 hours ago

  • Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody® drug discovery and development technology in rare diseases

    Tuesday June 28th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022

  • Voxdale opens Dutch branch at innovation hub Brainport Eindhoven

    Tuesday June 28th 2022

  • ImmuneWatch signs licence agreement with UAntwerp and UZA and officially becomes a university spin-off company

    Friday June 24th 2022

  • argenx receives positive CHMP opinion for efgartigimod for the treatment of adult patients with generalized myasthenia gravis in Europe

    Friday June 24th 2022

  • Charles River and Ziphius Vaccines collaborate to manufacture saRNA-based vaccine

    Thursday June 23rd 2022

  • Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry

    Thursday June 23rd 2022

  • Your news here?

  • Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

    Wednesday June 22nd 2022

  • Biocartis announces new agreement with AstraZeneca for the development and marketing of a companion diagnostic test for Tagrisso®

    Wednesday June 22nd 2022

  • IDDI announces RTSM partnership with Clario

    Wednesday June 22nd 2022


Strategic Partners